Portfolio companies

Portfolio companies

HEMEX investment portfolio.

The HEMEX portfolio consists of carefully selected ventures. We believe they will make a remarkable contribution to the healthcare of tomorrow. A big part of our portfolio contributes to the United Nations’ sustainable development goals (SDG 3,4; 3,7; and 3,d).

Annaida Technologies SA

#fertility #femtech #medtech
_

Annaida is a Swiss Healthtech company, who’s developed and patented a NMR technology, able to provide a fast, non-invasive and quantitative embryo screening, giving patients an improved overall IVF experience.

Founders

Gora Conley
(CEO & Co-founder)

Marco Grisi
(CTO & Co-founder)

Indications

Infertility treatment and reproductive health

Fundraising

Open for investments for Series A.

Target: 3.7

By 2030, ensure universal access to sexual and reproductive health-care services, including for family planning, information and education, and the integration of reproductive health into national strategies and programmes.

Indicator: 3.7.1

Proportion of women of reproductive age (aged 15-49 years) who have their need for family planning satisfied with modern methods.

ARTIDIS AG

#oncology #ivd
_

Artidis is a Swiss Healthtech company, who’s developed the first nanomechanical biomarker for cancer diagnosis and treatment optimization, with a platform that allows physicians to optimize diagnostics.

Founders

Marija Plodinec
(CEO & Board Member, Co-Founder)

Marko Loparic
(CMO & Head of Digital Health, Co-Founder)

Philipp Oertle
(Head of Research & Development, Co-Founder)

Tobias Appenzeller
(Head of Quality & Clinical Operations, Co-Founder)

Indications

Breast cancer

Fundraising

Open for investments for Series A.

Target: 3.4

By 2030, reduce by one third premature mortality from non-communicable diseases through prevention and treatment and promote mental health and well-being.

Indicator: 3.4.1

Mortality rate attributed to cardiovascular disease, cancer, diabetes or chronic respiratory disease.

aspivix SA

#femtech #medtech
_

Aspivix is a Swiss medical device startup, devoted to women’s healthcare. The company has created a substitute for the tenaculum, in order to improve the Gynecological experience.

Founders

Mathieu Horras
(CEO & Co-founder)

David Finci
(Co-founder)

Julien Finci
(Co-founder)

Indications

IUD procedures

Fundraising

Open for investments for Series A.

Target: 3.7

By 2030, ensure universal access to sexual and reproductive health-care services, including for family planning, information and education, and the integration of reproductive health into national strategies and programmes.

Indicator: 3.7.1

Proportion of women of reproductive age (aged 15-49 years) who have their need for family planning satisfied with modern methods.

BioReperia AB

#oncology #ivd
_

BioReperia is a Swedish biotech company, based also in Switzerland, dedicated to provide services that accelerate anti-cancer drug discovery, assisting in selecting candidates efficiently and rapidly.

Founders

Lasse Jensen
(Co-founder)

Indications

Bladder cancer

Fundraising

Open for investments for Series A.

Target: 3.4

By 2030, reduce by one third premature mortality from non-communicable diseases through prevention and treatment and promote mental health and well-being.

Indicator: 3.4.1

Mortality rate attributed to cardiovascular disease, cancer, diabetes or chronic respiratory disease.

Cellestia Biotech AG

#oncology #R&D
_

Cellestia Biotech is a research and development company that develops innovative first-in-class therapies by selectively inhibiting transcription factors in the cell nucleus in multiple disease areas. Currently, their lead compound CB-103 is in Phase 2 of clinical trials and successfully treating cancer patients who are resistant to multi-drug treatments.

Founders

Rajwinder Lehal
(CEO & Co-founder)

Indications

Solid Tumors and Leukemia

Fundraising

Currently not fundraising.

Target: 3.4

By 2030, reduce by one third premature mortality from non-communicable diseases through prevention and treatment and promote mental health and well-being.

Indicator: 3.4.1

Mortality rate attributed to cardiovascular disease, cancer, diabetes or chronic respiratory disease.

hemotune AG

#dialysis #medtech
_

hemotune AG is a spin-off company originating out of the Functional Materials Lab at ETH Zurich. It has designed a multi-target precision medicine blood purification treatment to restore immune balance in septic shock and improve patient outcomes.

Founders

Carlos Mora
(Co-founder)

Lukas Langenegger
(Co-founder)

Indications

Sepsis

Fundraising

Currently not fundraising.

Target: 3.d

Strengthen the capacity of all countries, in particular developing countries, for early warning, risk reduction and management of national and global health risks.

Indicator: 3.d.2

Percentage of bloodstream infections due to selected antimicrobial-resistant organisms.

Hi-D Imaging AG

#cardiovascular #medtech #digitalhealth

Hi-D imaging is a Swiss medtech startup. HI-D is developing a new technology, supported by AI, that aims to revolutionize the medical imaging sector by reducing pre-operational/surgical planning complexity.

Founders

Özge Karakaş
(Co-founder)

Utku Gülan
(Co-founder)

Indications

Pre-operational surgery and risk assessment for cardiac operations.

Fundraising

Open for investments for Seed Series.

Target: 3.4

By 2030, reduce by one third premature mortality from non-communicable diseases through prevention and treatment and promote mental health and well-being.

Indicator: 3.4.1

Mortality rate attributed to cardiovascular disease, cancer, diabetes or chronic respiratory disease.

inQbator AG

#incubator #accelerator #funding_

inQbator AG is a start-up accelerator that seeks the most promising innovative companies and help them grow through accelerator programs offering hands-on mentoring, specialized services and access to funding.

Founders

HEMEX, BLKB, Launchpad

Inura Medical AG

#femtech #pharma
_

Inura Medical is a Swiss biopharma company, developing the first-of-a-kind urethral ovulum to treat patients who suffer from overactive bladder (OAB).

Founders

Professor Grant S. Mulholland (†)
(Founder)

Vanja Ivancevic
(CEO)

Indications

Overactive bladder

Fundraising

Open for investments for Series A.

Resistell AG

#ivd #amr
_

Resistell is a Swiss medtech startup, working on a solution for SEPSIS. They’ve patented a technology able to deliver AST diagnostic results in hours instead of days, allowing clinicians to halt sepsis by providing the right treatment to the patient on time.

Founders

Danuta Cichocka
(CEO & Co-founder)

Giovanni Dietler
(Inventor, Co-founder)

Sandor Kasas
(Inventor, Co-founder)

Indications

Sepsis

Fundraising

Open for investments for Series B.

Target: 3.d

Strengthen the capacity of all countries, in particular developing countries, for early warning, risk reduction and management of national and global health risks.

Indicator: 3.d.2

Percentage of bloodstream infections due to selected antimicrobial-resistant organisms.

Scailyte AG

#ivd #digitalhealth
_

Scailyte is a Swiss biotech company, the startup, with a data driven approach, is working on a solution that provides unprecedented insight into diseases and enables ultra-sensitive diagnostics by uncovering human’s hidden “single-cell” secrets.

Founders

Peter Nestorov
(CEO & Co-founder)

Manfred Claassen
(Co-founder)

Indications

  • Sezary Syndrome (CTCL)
  • Endometriosis
  • ARDS
  • Non-small Cell Lung Cancer (NSCLC)
  • DLBCL (CAR-T cells)

Fundraising

Open for investments for Series A.

Sleepiz AG

#medtech
_

Sleepiz is a Swiss medtech startup, working on a device that operates in a non-contact fashion and measures movements originating from heart contractions and breathing patterns, as well as body motions with medical grade accuracy.

Founders

Soumya Sunder Dash
(CEO & Co-founder)

Max Sieghold
(Co-founder)

Marc Rullan
(CTO & Co-founder)

Indications

  • Sleep Apnea
  • Chronic respiratory diseases
  • COVID-19

Fundraising

Currently not fundraising.

Target: 3.4

By 2030, reduce by one third premature mortality from non-communicable diseases through prevention and treatment and promote mental health and well-being.

Indicator: 3.4.1

Mortality rate attributed to cardiovascular disease, cancer, diabetes or chronic respiratory disease.

TOLREMO therapeutics AG

#biotech #oncology
_

Tolremo is a Swiss biotechnology company. Based on cutting-edge science and guided by pioneering real-world medicine, the company created a broad cancer drug resistance platform that provides a unique entry point into a major clinical problem.

Founders

Stefanie Flückiger-Mangual
(CEO & Co-founder)

Indications

Resistance preventing precision therapies to patients with cancer.

Fundraising

Fundraising Series A2.

Target: 3.4

By 2030, reduce by one third premature mortality from non-communicable diseases through prevention and treatment and promote mental health and well-being.

Indicator: 3.4.1

Mortality rate attributed to cardiovascular disease, cancer, diabetes or chronic respiratory disease.

Get funding with our solutions